The Motley Fool on MSN9h
Got $5,000? Viking Therapeutics Stock Just Got a Big New Green Flag
With a gain of more than 531% over the last 12 months, shares of Viking Therapeutics (NASDAQ: VKTX) are a hot commodity, to ...
Viking Therapeutics’ weight-loss pill shows ‘great outcome’ in trial
Viking Therapeutics Inc. cheered analysts Monday after the biotech posted data on its oral weight-loss drug showing ...
Viking Therapeutics stock falling amid results for new GLP-1 pill
Viking Therapeutics (VKTX) shares are taking a dive in Monday's session despite on rising manufacturing concerns and ...
The Motley Fool on MSN2d
Is Viking Therepautics a Buy Now?
Viking Therapeutics reported clinical trial data on Sunday, which excited some investors. Despite signs that Viking's ...
MM&M3d
Viking Therapeutics’ GLP-1 pill candidate shows promise in latest study
Viking Therapeutics’ GLP-1 pill candidate for treating obesity showed promise in its latest trial results, the clinical-stage ...
bovnews1d
Viking Therapeutics Inc (VKTX) Stock: More Resilient Than It Appears
On Tuesday, Viking Therapeutics Inc (VKTX) stock saw a modest uptick, ending the day at $64.63 which represents a slight increase of $1.49 or 2.36% from the prior close of $63.14. The stock opened at ...
Promising Clinical Developments and Strong Financial Position Support Buy Rating for Tenaya Therapeutics
Analyst Michael Ulz of Morgan Stanley maintained a Buy rating on Tenaya Therapeutics (TNYA – Research Report), retaining the price target ...
Hosted on MSN3d
Viking Therapeutics Tumbles As Obesity Competition Sabotages Its Novo Nordisk Beat
Viking Therapeutics' highly anticipated weight-loss pill topped Wall Street's expectations — and a rival pill from Novo ...